Journal of Applied and Integrative Biology
ISSN: 3139-1567 (Online)
Department of Biotechnology, Motilal Nehru National Institute of Technology Allahabad, India
*Corresponding author: amani@mnnit.ac.in
Received: 12 Nov 2025 | Accepted: 22 Dec 2025 | Published: 26 Dec 2025
Pancreatic adenocarcinoma (PAAD) is among the most aggressive malignancies and is associated with poor prognosis due to late diagnosis. This study analyzed RNA-Seq data from TCGA to identify differentially expressed genes (DEGs). A total of 418 DEGs were identified, with enrichment in immune-related processes. Network analysis identified hub genes including PTPN6, which showed significant association with patient survival. These findings highlight potential biomarkers and therapeutic targets.
Pancreatic adenocarcinoma, TCGA, RNA-Seq, Differentially expressed genes, Network analysis, PTPN6
Pancreatic adenocarcinoma is one of the most lethal malignancies with a five-year survival rate below 10%. Advances in transcriptomics have enabled systematic identification of dysregulated genes and pathways. This study aims to identify DEGs and key molecular mechanisms involved in disease progression.
RNA-Seq data from TCGA-PAAD were analyzed using Bioconductor tools. Differential expression analysis was performed using glmLRT. Functional enrichment was conducted using ShinyGO, and protein interaction networks were analyzed using STRING and Cytoscape.
A total of 418 DEGs were identified, including 410 upregulated and 8 downregulated genes. Enrichment analysis revealed immune-related pathways. Hub genes such as PTPN6 showed significant clinical relevance.
The study highlights the importance of immune-related pathways in pancreatic cancer. PTPN6 was identified as a key prognostic marker, suggesting its potential role in disease progression.
This study provides insights into molecular mechanisms of pancreatic adenocarcinoma and identifies PTPN6 as a potential biomarker and therapeutic target.
(Include full reference list as in PDF)
Download Full PDF